Savara Inc (SVRA) News

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

-- Completed Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment...

Form 8-K - Current report

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

Includes $30M at Close to Refinance Existing Debt Facility Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company...

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

-- Priority Review Was Requested, Commercial Launch Preparations Underway -- -- MOLBREEVI Has the Potential to Be the First and Only Approved...

Form 3 - Initial statement of beneficial ownership of securities

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

-- Company to Host Industry Theater on aPAP with Two World-Renowned Experts -- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

-- Real World, Retrospective Outcomes Data Suggest Molgramostim Addresses the Underlying Pathophysiology of aPAP Resulting in Improved Lung...

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that...